News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,125 Results
Type
Article (14126)
Company Profile (282)
Press Release (250717)
Section
Business (79466)
Career Advice (152)
Deals (13221)
Drug Delivery (35)
Drug Development (50412)
Employer Resources (31)
FDA (5706)
Job Trends (5125)
News (144314)
Policy (10025)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (906)
Accelerated approval (2)
Adcomms (12)
Allergies (48)
Alliances (21615)
ALS (53)
Alzheimer's disease (805)
Antibody-drug conjugate (ADC) (79)
Approvals (5712)
Artificial intelligence (99)
Autoimmune disease (7)
Automation (5)
Bankruptcy (102)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (35)
Biotechnology (232)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (132)
Cancer (1160)
Cardiovascular disease (92)
Career advice (132)
Career pathing (2)
CAR-T (100)
Cell therapy (290)
Cervical cancer (5)
Clinical research (40642)
Collaboration (459)
Compensation (188)
Complete response letters (13)
COVID-19 (1028)
CRISPR (33)
C-suite (127)
Cystic fibrosis (75)
Data (1198)
Denatured (11)
Depression (26)
Diabetes (110)
Diagnostics (1283)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (71)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (60)
Earnings (29347)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (47838)
Executive appointments (372)
FDA (6245)
Featured Employer (34)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (428)
Gene editing (79)
Generative AI (9)
Gene therapy (210)
GLP-1 (341)
Government (1072)
Grass and pollen (2)
Guidances (17)
Healthcare (6582)
Huntington's disease (21)
IgA nephropathy (18)
Immunology and inflammation (69)
Indications (16)
Infectious disease (1082)
Inflammatory bowel disease (106)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (50)
Interviews (17)
IPO (7251)
IRA (11)
Job creations (859)
Job search strategy (127)
Kidney cancer (6)
Labor market (3)
Layoffs (197)
Leadership (2)
Legal (1384)
Liver cancer (28)
Lung cancer (165)
Lymphoma (74)
Machine learning (1)
Management (7)
Manufacturing (105)
MASH (46)
Medical device (2582)
Medtech (2583)
Mergers & acquisitions (6214)
Metabolic disorders (330)
Multiple sclerosis (45)
NASH (13)
Neurodegenerative disease (51)
Neuropsychiatric disorders (21)
Neuroscience (1136)
NextGen: Class of 2025 (2014)
Non-profit (852)
Northern California (1402)
Now hiring (19)
Obesity (171)
Opinion (98)
Ovarian cancer (50)
Pain (38)
Pancreatic cancer (47)
Parkinson's disease (92)
Partnered (6)
Patents (95)
Patient recruitment (54)
Peanut (35)
People (25401)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14347)
Phase II (18909)
Phase III (11947)
Pipeline (566)
Podcasts (41)
Policy (30)
Postmarket research (852)
Preclinical (6011)
Press Release (30)
Prostate cancer (49)
Psychedelics (35)
Radiopharmaceuticals (210)
Rare diseases (256)
Real estate (1414)
Recruiting (12)
Regulatory (8481)
Reports (14)
Research institute (935)
Resumes & cover letters (17)
Rett syndrome (2)
RNA editing (1)
RSV (10)
Schizophrenia (52)
Series A (85)
Series B (51)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1243)
Special edition (10)
Sponsored (11)
Startups (1969)
State (1)
Stomach cancer (4)
Supply chain (17)
The Weekly (30)
United States (11042)
Vaccines (193)
Venture capitalists (27)
Webinars (7)
Weight loss (97)
Women's health (14)
Worklife (2)
Date
Today (118)
Last 7 days (477)
Last 30 days (1696)
Last 365 days (20394)
2025 (3303)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (37)
Alaska (2)
Arizona (50)
Arkansas (5)
Asia (17130)
Australia (2899)
California (3193)
Canada (988)
China (284)
Colorado (123)
Connecticut (135)
Delaware (77)
Europe (36844)
Florida (371)
Georgia (94)
Idaho (16)
Illinois (198)
India (5)
Indiana (78)
Iowa (1)
Japan (62)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (10)
Maryland (413)
Massachusetts (2529)
Michigan (68)
Minnesota (124)
Mississippi (1)
Missouri (21)
Montana (14)
Nebraska (4)
Nevada (14)
New Hampshire (13)
New Jersey (798)
New Mexico (11)
New York (878)
North Carolina (491)
North Dakota (4)
Northern California (1402)
Ohio (102)
Oklahoma (8)
Oregon (21)
Pennsylvania (598)
Puerto Rico (1)
Rhode Island (12)
South America (207)
South Carolina (3)
Southern California (1243)
Tennessee (24)
Texas (355)
Utah (45)
Virginia (63)
Washington D.C. (27)
Washington State (298)
Wisconsin (13)
265,125 Results for "tavros therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
January 8, 2025
·
6 min read
Bio NC
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compounds
Tavros Therapeutics, Inc., a precision oncology platform company, announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG.
May 14, 2024
·
3 min read
Business
Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Tavros Therapeutics, Inc. and OpenBench, Inc. today announced the companies have entered into a collaboration agreement to discover small molecule modulators of up to five oncology targets across an initial 18-month term.
April 27, 2023
·
3 min read
Bio NC
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Tavros Therapeutics today announced the completion of a $7.5 million oversubscribed Seed II financing.
September 27, 2022
·
2 min read
Business
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs
Tavros Therapeutics, Inc. and Vividion Therapeutics, Inc. today announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial five-year term.
October 12, 2022
·
5 min read
Business
Bayer’s Vividion Bets up to $930M for Tavros Oncology Partnership
Vividion Therapeutics and Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.
October 12, 2022
·
2 min read
·
Tristan Manalac
Business
OpenBench and Tavros Therapeutics Announce Collaboration to Pursue First-in-class Cancer Target
Tavros Therapeutics, and OpenBench, today announced a collaboration in which OpenBench will identify novel, potent antagonists against an undisclosed cancer target that was identified by Tavros’s proprietary functional genomics platform.
December 2, 2021
·
2 min read
Press Releases
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
January 22, 2025
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Repare Therapeutics to Cut Staff Again, This Time by 75%
The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.
February 25, 2025
·
2 min read
·
Angela Gabriel
1 of 26,513
Next
